CA2319310A1 - Equine fc epsilon receptor alpha chain nucleic acid molecules, corresponding proteins and uses thereof - Google Patents

Equine fc epsilon receptor alpha chain nucleic acid molecules, corresponding proteins and uses thereof Download PDF

Info

Publication number
CA2319310A1
CA2319310A1 CA002319310A CA2319310A CA2319310A1 CA 2319310 A1 CA2319310 A1 CA 2319310A1 CA 002319310 A CA002319310 A CA 002319310A CA 2319310 A CA2319310 A CA 2319310A CA 2319310 A1 CA2319310 A1 CA 2319310A1
Authority
CA
Canada
Prior art keywords
epsilon
protein
alpha
ige
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002319310A
Other languages
French (fr)
Other versions
CA2319310C (en
Inventor
Eric R. Weber
Catherine A. Mccall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Heska Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2319310A1 publication Critical patent/CA2319310A1/en
Application granted granted Critical
Publication of CA2319310C publication Critical patent/CA2319310C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/862—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to equine Fc epsilon receptor alpha chain nucleic acid molecules, proteins encoded by such nucleic acid molecules, antibodies raised against such proteins, and inhibitors of such proteins. The present invention also includes methods to detect IgE using such proteins and antibodies. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to mediate Fc epsilon receptor-mediated biological responses.

Claims (70)

1. An isolated nucleic acid molecule encoding an equine Fc.epsilon.R.alpha.
protein.
2. An isolated nucleic acid molecule selected from the group consisting of: a nucleic acid molecule that comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID
NO:6, SEQ ID NO:8 and SEQ ID NO:11; and a nucleic acid molecule comprising an allelic variant of a nucleic acid molecule comprising any of said nucleic acid sequences.
3. An isolated equine Fc.epsilon.R.alpha. protein.
4. A method to produce an equine Fc.epsilon.R.alpha. protein, said method comprising culturing a cell transformed with a nucleic acid molecule encoding an equine Fc.epsilon.R.alpha.
protein.
5. A method to detect IgE comprising:
(a) contacting an isolated equine Fc.epsilon.R.alpha. protein with a putative IgE-containing composition under conditions suitable for formation of a Fc.epsilon.R.alpha. protein:IgE
complex; and (b) determining the presence of IgE by detecting said Fc.epsilon.R.alpha.
protein:IgE complex, the presence of said Fc.epsilon.R.alpha. protein:IgE
complex indicating the presence of IgE.
6. A kit for detecting IgE comprising an equine Fc.epsilon.R.alpha. protein and a means for detecting IgE.
7. An inhibitor that interferes with formation of a complex between equine Fc.epsilon.R.alpha. protein and IgE, wherein said inhibitor is identified by its ability to interfere with said complex formation.
8. A method to identify a compound that interferes with formation of a complex between equine Fc.epsilon.R.alpha. protein and IgE, said method comprising:
(a) contacting an isolated equine Fc.epsilon.R.alpha. protein with a putative inhibitory compound under conditions in which, in the absence of said compound, said equine Fc.epsilon.R.alpha. protein forms a complex with IgE; and (b) determining if said putative inhibitory compound inhibits said complex formation.
9. A test kit to identify a compound capable of interfering with formation of a complex between an equine Fc.epsilon.R.alpha. protein and IgE, said test kit comprising an isolated equine Fc.epsilon.R.alpha. protein that can complex with IgE and a means for determining the extent of interference of said complex formation in the presence of a putative inhibitory compound.
10. A therapeutic composition that, when administered to an animal, reduces Fc epsilon receptor-mediated biological responses, said therapeutic composition comprising a therapeutic compound selected from the group consisting of:
an isolated equine Fc.epsilon.R.alpha. protein; a mimetope of an equine Fc.epsilon.R.alpha. protein; an isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with an equine Fc.epsilon.R.alpha. gene; an isolated antibody that selectively binds to an equine Fc.epsilon.R.alpha.
protein; and an inhibitor that interferes with formation of a complex between an equine Fc.epsilon.R.alpha. protein and IgE.
11. A method to reduce Fc epsilon receptor-mediated biological responses in an animal comprising administering to an animal a therapeutic composition comprising a therapeutic compound selected from the group consisting of: an isolated equine Fc.epsilon.R.alpha. protein; a mimetope of an equine Fc.epsilon.R.alpha. protein; an isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with an equine Fc.epsilon.R.alpha.
gene; an isolated antibody that selectively binds to an equine Fc.epsilon.R.alpha. protein; and an inhibitor that interferes with formation of a complex between an equine Fc.epsilon.R.alpha. protein and IgE.
12. The nucleic acid molecule of Claim 1, wherein said equine Fc.epsilon.R.alpha. protein is selected from the group consisting of: a protein that comprises an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:7 and SEQ
ID NO:12; and a protein encoded by an allelic variant of a nucleic acid molecule encoding a protein comprising any of said amino acid sequences.
13. An isolated nucleic acid molecule which is fully complementary to the nucleic acid molecule of Claim 1.
14. The invention of Claim 1, 3 or 4, wherein said protein comprises an IgE
binding domain, wherein said domain is able to bind to IgE.
15. The nucleic acid molecule of Claim 1, wherein said nucleic acid molecule comprises a nucleic acid sequence that is at least about 80% identical to a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ
ID
NO:6 and SEQ ID NO:11.
16. The invention of Claim 1, 4 or 6, wherein said nucleic acid molecule is selected from the group consisting of neqFc.epsilon.R.alpha.1015, neqFc.epsilon.R.alpha.765, neqFc.epsilon.R.alpha.708 and neqFc.epsilon.R.alpha.603.
17. The nucleic acid molecule of Claim 1, wherein said nucleic acid molecule is selected from the group consisting of a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ
ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8 and SEQ ID NO:11; and a nucleic acid molecule comprising an allelic variant of a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ
ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8 and SEQ ID
NO:11.
18. A recombinant molecule comprising a nucleic acid molecule as set forth in Claim 1 or 2 operatively linked to a transcription control sequence.
19. A recombinant virus comprising a nucleic acid molecule as set forth in Claim 1 or 2.
20. A recombinant cell comprising a nucleic acid molecule as set forth in Claim 1 or 2
21. The nucleic acid molecule of Claim 1 or 2, wherein said nucleic acid molecule is selected from the group consisting of: a nucleic acid molecule that comprises a nucleic acid sequence selected from the group consisting of SEQ ID
NO:6, SEQ ID NO:8 and SEQ ID NO:11; and a nucleic acid molecule comprising an allelic variant of a nucleic acid sequence selected from the group consisting of SEQ
ID NO:6, SEQ ID NO:8 and SEQ ID NO:11.
22. The invention of Claim 3, 4, 5 or 6, wherein said protein is encoded by a nucleic acid molecule comprising a nucleic acid sequence that is at least about 80%
identical to a nucleic acid sequence selected from the group consisting of :
SEQ ID
NO:1, SEQ ID NO:4, SEQ ID NO:6 and SEQ ID NO:11.
23. The invention of Claim 3, 4, 5 or 6, wherein sand protein is selected from the group consisting of a protein encoded by a nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ
ID NO:6 and SEQ ID NO:11; and a protein encoded by a nucleic acid molecule comprising an allelic variant of a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ
ID
NO:6 and SEQ ID NO:11.
24. The invention of Claim 3, 4, 5 or 6, wherein said protein comprises an amino acid sequence that is at least about 65% identical to an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:7 and SEQ ID
NO:12.
25. The invention of Claim 3, 4, 5 or 6, wherein said protein is selected from the group consisting of a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:7 and SEQ ID NO:12; and a protein encoded by an allelic variant of a nucleic acid molecule encoding a protein comprising any of said amino acid sequences.
26. The invention of Claim 3, 4, 5 or 6, wherein said equine Fc.epsilon.R.alpha. protein comprises a protein selected from the group consisting of PequFc.epsilon.R.alpha.255, PequFc.epsilon.R.alpha.236 and PequFc.epsilon.R.alpha.201.
27. An isolated antibody that selectively binds to a protein as set forth in Claim 3.
28. The invention of Claim 3, 4, 5 or 6, wherein said Fc.epsilon.R.alpha.
protein is encoded by a nucleic acid molecule selected from the group consisting of neqFc.epsilon.R.alpha.1015, neqFc.epsilon.R.alpha.765, neqFc.epsilon.R.alpha.708 and neqFc.epsilon.R.alpha.603.
29. The invention of Claim 3, 5 or 6, wherein said Fc.epsilon.R.alpha. protein is conjugated to a detectable marker.
30. The invention of Claim 29, wherein said detectable marker is connected to said Fc.epsilon.R.alpha. protein by chemical conjugation or recombinant DNA
technology.
31. The invention of Claim 3, 5 or 6, wherein said Fc.epsilon.R.alpha. protein is conjugated to a detectable marker selected from the group consisting of a radioactive label, an enzyme, a fluorescent label, a chemiluminescent label, a chromophoric label and a ligand.
32. The invention of Claim 3, 5 or 6, wherein said Fc.epsilon.R.alpha. protein is conjugated to a detectable marker selected from the group consisting of fluorescein, a radioisotope, a phosphatase, biotin, biotin-related compounds, avidin, avidin-related compounds and a peroxidase.
33. The invention of Claim 3, 5 or 6, wherein a carbohydrate group of said Fc.epsilon.R.alpha. protein is conjugated to biotin.
34. The method of Claim 4, wherein said nucleic acid molecule is selected from the group consisting of a nucleic acid molecule that comprises a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:4, SEQ
ID
NO:6 and SEQ ID NO:11; and an allelic variant of a nucleic acid molecule comprising any of said nucleic acid sequences.
35. The method of Claim 4, wherein said cell is S. frugiperda pFB-neqFc.epsilon.RI.alpha.608.
36. The method of Claim 5, wherein said putative IgE-containing composition comprises a composition selected from the group consisting of blood, serum, plasma, urine, tears, aqueous humor, cerebrospinal fluid, saliva, lymph, nasal secretions, tracheobronchial aspirates, milk and feces.
37. The method of Claim 5, wherein said putative IgE-containing composition comprises serum.
38. The method of Claim 5, wherein said putative IgE-containing composition comprises a cell that produces IgE.
39. The method of Claim 5, wherein said putative IgE-containing composition comprises a myeloma cell.
40. The method of Claim 5, further comprising the step selected from the group consisting of immobilizing said Fc.epsilon.R.alpha. protein on a substrate prior to performing step (a) to form a Fc.epsilon.R.alpha. protein-immobilized substrate; and binding said putative IgE-containing composition on a substrate prior to performing step (a) to form a putative IgE-containing composition-bound substrate, wherein said substrate is selected from the group consisting of a non-coated substrate, a Fc.epsilon.R.alpha. protein-immobilized substrate, an antigen-immobilized substrate and an anti-IgE antibody-immobilized substrate.
41. The method of Claim 40, wherein said antigen is selected from the group consisting of an allergen and a parasitic antigen.
42. The method of Claim 40, further comprising removing non-bound material from said antigen-immobilized substrate or said anti-IgE antibody-immobilized substrate under conditions that retain antigen or antibody binding to said substrate.
43. The method of Claim 40, wherein said substrate comprises a material selected from the group consisting of plastic, glass, gel, celluloid, paper and particulate material.
44. The method of Claim 40, wherein said substrate material is selected from the group consisting of latex, polystyrene, nylon, nitrocellulose, agarose and magnetic resin.
45. The method of Claim 40, wherein said substrate comprises a shape selected from the group consisting of a well, a plate, a dipstick, a bead, a lateral flow apparatus, a membrane, a filter, a tube, a dish, a celluloid-type matrix and a magnetic particle.
46. The method of Claim 40, wherein said substrate comprises an ELISA
plate, a dipstick, a radioimmunoassay plate, agarose beads, plastic beads, latex beads, immunoblot membranes and immunoblot papers.
47. The method of Claim 5, wherein said step of detecting comprises performing assays selected from the group consisting of enzyme-linked immunoassays, radioimmunoassays, immunoprecipitations, fluorescence immunoassays, chemiluminescent assays, immunoblot assays, lateral flow assays, agglutination assays and particulate-based assays.
48. The method of Claim 5, wherein said step of detecting comprises:
(a) contacting said Fc.epsilon.R.alpha. protein:IgE complex with an indicator molecule that binds selectively to said Fc.epsilon.R.alpha. protein:IgE
complex;
(b) removing substantially all of said indicator molecule that does not selectively bind to Fc.epsilon.R.alpha. protein:IgE complex; and (c) detecting said indicator molecule, wherein presence of said indicator molecule is indicative of the presence of IgE.
49. The method of Claim 48, wherein said indicator molecule comprises a compound selected from the group consisting of an antigen, an antibody and a lectin.
50. The method of Claim 5, said method comprising the steps of:
(a) immobilizing said Fc.epsilon.R.alpha. protein on a substrate;
(b) contacting said Fc.epsilon.R.alpha. protein with said putative IgE-containing composition under conditions suitable for formation of a Fc.epsilon.R.alpha.
protein:IgE complex bound to said substrate;
(c) removing non-bound material from said substrate under conditions that retain Fc.epsilon.R.alpha. protein:IgE complex binding to said substrate; and (d) detecting the presence of said Fc.epsilon.R.alpha. protein:IgE complex.
51. The method of Claim 50, wherein the presence of said Fc.epsilon.R.alpha.
protein:IgE complex is detected by contacting said Fc.epsilon.R.alpha.
protein:IgE complex with a compound selected from the group consisting of an antigen and an antibody that binds selectively to IgE.
52. The method of Claim 51, wherein said compound comprises a detectable marker.
53. The method of Claim 5, said method comprising the steps of:
(a) immobilizing a specific antigen on a substrate;
(b) contacting said antigen with said putative IgE-containing composition under conditions suitable for formation of an antigen:IgE complex bound to said substrate;
(c) removing non-bound material from said substrate under conditions that retain antigen:IgE complex binding to said substrate; and (d) detecting the presence of said antigen:IgE complex by contacting said antigen:IgE complex with said Fc.epsilon.R.alpha. protein.
54. The method of Claim 5, said method comprising the steps of:
(a) immobilizing an antibody that binds selectively to IgE on a substrate;

(b) contacting said antibody with said putative IgE-containing composition under conditions suitable for formation of an antibody:IgE complex bound to said substrate;
(c) removing non-bound material from said substrate under conditions that retain antibody:IgE complex binding to said substrate; and (d) detecting the presence of said antibody:IgE complex by contacting said antibody:IgE complex with said Fc.epsilon.R.alpha. protein.
55. The method of Claim 53 or 54, wherein said Fc.epsilon.R.alpha. protein is conjugated to a detectable marker selected from the group consisting of fluorescein, a radioisotope, a phosphatase, biotin, a biotin-related compound, avidin, an avidin-related compound and peroxidase.
56. The method of Claim 5, said method comprising the steps of:
(a) immobilizing said putative IgE-containing composition on a substrate;
(b) contacting said composition with said Fc.epsilon.R.alpha. protein under conditions suitable for formation of a Fc.epsilon.R.alpha. protein:IgE complex bound to said substrate;
(c) removing non-bound material from said substrate under conditions that retain Fc.epsilon.R.alpha. protein:IgE complex binding to said substrate; and (d) detecting the presence of said Fc.epsilon.R.alpha. protein:IgE complex.
57. The method of Claim 56, wherein the presence of said Fc.epsilon.R.alpha.
protein:IgE complex is detected by contacting said Fc.epsilon.R.alpha.
protein:IgE complex with an indicator molecule selected from the group consisting of an anti-equine Fc.epsilon.R.alpha.
antibody, an antigen and a lectin.
58. The method of Claim 56, wherein said Fc.epsilon.R.alpha. protein comprises a detectable marker.
59. The method of Claim 5, wherein said method is performed in solution.
60. The method of Claim 5, said method comprising the steps of:

yeasts, fleas, flies, mosquitos, mites, midges, biting gnats, lice, bees, wasps, ants, true bugs or ticks.
71. The kit of Claim 61, wherein said parasite antigen is a Culicoides antigen.
72. The kit of Claim 6 further comprising an apparatus comprising:
(a) a support structure defining a flow path;
(b) a labeling reagent comprising a bead conjugated to said antigen, wherein said labeling reagent is impregnated within the support structure in a labeling zone; and (c) a capture reagent comprising said Fc.epsilon.R.alpha. protein, wherein said capture reagent is located downstream of said labeling reagent within a capture zone fluidly connected to said labeling zone in such a manner that said labeling reagent can flow from said labeling zone into said capture zone.
73. The kit of Claim 72, wherein said apparatus further comprises a sample receiving zone located along said flow path.
74. The kit of Claim 72, wherein said apparatus further comprises an absorbent located at the end of said flow path.
75. The kit of Claim 73, wherein said sample receiving zone is located upstream of said labeling reagent.
76. The kit of Claim 72, wherein said support structure comprises a material that does not impede the flow of said bead from said labeling zone to said capture zone.
77. The kit of Claim 72, wherein said support structure comprises an ionic material.
78. The kit of Claim 72, wherein said support structure comprises a material selected from the group consisting of nitrocellulose, PVDF and carboxymethylcellulose.
79. The kit of Claim 72, wherein said bead comprises a latex bead.
80. The kit of Claim 72, wherein said labeling reagent is dried within said labeling zone and said capture reagent is dried within said capture zone.

(a) contacting a recombinant cell with said putative IgE-containing composition under conditions suitable for formation of a recombinant cell:IgE
complex, wherein said recombinant cell comprises an equine Fc.epsilon.R.alpha.
protein; and (b) determining the presence of IgE by detecting said recombinant cell:IgE complex, the presence of said recombinant cell:IgE complex indicating the presence of IgE.
61. The kit of Claim 6, wherein said detection means further comprises an antigen selected from the group consisting of an allergen and a parasite antigen, wherein said antigen induces IgE antibody production in animals.
62. The kit of Claim 6, wherein said detection means comprises an antibody that selectively binds to an IgE.
63. The kit of Claim 6, wherein said detection means detects said Fc.epsilon.R.alpha.
protein.
64. The kit of Claim 6, wherein said Fc.epsilon.R.alpha. protein is connected to a detectable marker by chemical conjugation or recombinant DNA technology.
65. The kit of Claim 6, wherein said Fc.epsilon.R.alpha. protein is conjugated to biotin.
66. The kit of Claim 6, wherein said Fc.epsilon.R.alpha. protein is on the surface of a recombinant cell that comprises said Fc.epsilon.R.alpha. protein.
67. The kit of Claim 61, wherein said antigen is immobilized on a substrate.
68. The kit of Claim 67, wherein said substrate comprises a material selected from the group consisting of plastic, glass, gel, celluloid, paper and particulate material.
69. The kit of Claim 67, wherein said substrate comprises a shape selected from the group consisting of a well, a plate, a dipstick, a bead, a lateral flow apparatus, a membrane, a filter, a tube, a dish, a celluloid-type matrix and a magnetic particle.
70. The kit of Claim 61, wherein said allergen is derived from material selected from the group consisting of fungi, rusts, smuts, bacteria, trees, weeds, shrubs, grasses, wheat, corn, grains, hays, straws, oats, alfalfa, clovers, soybeans, 81. The inhibitor of Claim 7, wherein said inhibitor inhibits said complex formation.
82. The inhibitor of Claim 7, wherein said inhibitor prevents histamine release by a cell when said equine Fc.epsilon.R.alpha. protein is associated with said cell.
83. The inhibitor of Claim 7, wherein said inhibitor is selected from the group consisting of a substrate analog of an equine Fc.epsilon.R.alpha.
protein, a mimetope of an equine Fc.epsilon.R.alpha. protein and a soluble portion of an equine Fc.epsilon.R.alpha. protein.
84. The inhibitor of Claim 7, wherein said inhibitor comprises a peptidomimetic compound.
85. The invention of Claim 10 or 11, wherein said equine Fc.epsilon.R.alpha.
protein is selected from the group consisting of: a peptide of an equine Fc.epsilon.R.alpha. protein that binds to IgE; and a soluble portion of an equine Fc.epsilon.R.alpha. protein that binds to IgE.
86. The invention of Claim 10 or 11, wherein said composition further comprises a component selected from the group consisting of an excipient, an adjuvant, and a carrier.
87. The invention of Claim 10 or 11, wherein said inhibitor is selected from the group consisting of: a substrate analog of an equine Fc.epsilon.R.alpha.
protein; a mimetope of an equine FcERa protein; and a soluble portion of an equine Fc.epsilon.R.alpha. protein that binds to IgE.
CA2319310A 1998-01-29 1999-01-28 Equine fc epsilon receptor alpha chain nucleic acid molecules, corresponding proteins and uses thereof Expired - Lifetime CA2319310C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/015,734 US6057127A (en) 1998-01-29 1998-01-29 Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof
US09/015,734 1998-01-29
PCT/US1999/001903 WO1999038974A1 (en) 1998-01-29 1999-01-28 EQUINE Fc EPSILON RECEPTOR ALPHA CHAIN NUCLEIC ACID MOLECULES, CORRESPONDING PROTEINS AND USES THEREOF

Publications (2)

Publication Number Publication Date
CA2319310A1 true CA2319310A1 (en) 1999-08-05
CA2319310C CA2319310C (en) 2011-05-24

Family

ID=21773286

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2319310A Expired - Lifetime CA2319310C (en) 1998-01-29 1999-01-28 Equine fc epsilon receptor alpha chain nucleic acid molecules, corresponding proteins and uses thereof

Country Status (10)

Country Link
US (5) US6057127A (en)
EP (1) EP1051491B1 (en)
AT (1) ATE474047T1 (en)
AU (1) AU746218B2 (en)
CA (1) CA2319310C (en)
DE (1) DE69942575D1 (en)
DK (1) DK1051491T3 (en)
ES (1) ES2348971T3 (en)
PT (1) PT1051491E (en)
WO (1) WO1999038974A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057127A (en) * 1998-01-29 2000-05-02 Heska Corporation Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof
WO2001029078A2 (en) 1999-10-15 2001-04-26 Heska Corporation Method for production and use of mite group 1 proteins
US6889145B1 (en) 2000-03-15 2005-05-03 Northwestern University Three-dimensional model of a Fc region of an IgE antibody and uses thereof
WO2002006298A1 (en) * 2000-07-13 2002-01-24 Hyseq, Inc. Soluble immunoglobulin e receptor alpha like molecules
US6916626B1 (en) * 2001-04-25 2005-07-12 Rockeby Biomed Ltd. Detection of Candida
US6753303B2 (en) * 2001-12-06 2004-06-22 Hershey Entertainment & Resorts Company Whipped cocoa bath
EP2567973B1 (en) * 2005-11-28 2014-05-14 Zymogenetics, Inc. IL-21 antagonists
EP2109475B1 (en) * 2007-01-09 2019-11-27 Mystic Pharmaceuticals, Inc. Intranasal cartridge devices
US8329071B2 (en) * 2008-12-08 2012-12-11 Hestia Tec, Llc Multicomponent nanoparticle materials and process and apparatus therefor
US10940274B2 (en) * 2015-12-01 2021-03-09 Cipla Limited Nasal spray assembly
EP3192806A1 (en) 2016-01-13 2017-07-19 Affiris AG Alpha chain of the high-affinity ige receptor (fceria)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3956752A (en) * 1975-03-12 1976-05-11 Harris Corporation Polarization insensitive lens formed of spiral radiators
US4962035A (en) * 1987-12-01 1990-10-09 President And Fellows Of Harvard College DNA encoding IgE receptor alpha-subunit or fragment thereof
CA2000878C (en) * 1988-10-18 1999-06-29 Jean-Pierre Kinet Cdnas coding for the subunit of the high-affinity receptor for immunoglobulin e
WO1991006570A1 (en) * 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
CA2113813C (en) * 1991-08-14 2005-04-12 Paula M. Jardieu Immunoglobulin variants for specific fc epsilon receptors
US5770396A (en) * 1992-04-16 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E
FR2697485B1 (en) * 1992-11-02 1995-01-20 Valeo Vision Signaling light with modular luminous elements, for a motor vehicle.
US5945294A (en) * 1996-11-26 1999-08-31 Heska Corporation Method to detect IgE
US5958880A (en) * 1996-12-19 1999-09-28 Heska Corporation Feline Fc epsilon receptor alpha chain proteins and therapeutic uses thereof
US6057127A (en) * 1998-01-29 2000-05-02 Heska Corporation Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof

Also Published As

Publication number Publication date
ATE474047T1 (en) 2010-07-15
WO1999038974A1 (en) 1999-08-05
US6582701B1 (en) 2003-06-24
ES2348971T3 (en) 2010-12-17
US20030235579A1 (en) 2003-12-25
US6887672B2 (en) 2005-05-03
US6057127A (en) 2000-05-02
PT1051491E (en) 2010-08-20
US7226996B2 (en) 2007-06-05
US20070238196A1 (en) 2007-10-11
US20050170466A1 (en) 2005-08-04
AU2567499A (en) 1999-08-16
CA2319310C (en) 2011-05-24
EP1051491A1 (en) 2000-11-15
EP1051491B1 (en) 2010-07-14
AU746218B2 (en) 2002-04-18
DE69942575D1 (en) 2010-08-26
DK1051491T3 (en) 2010-08-16

Similar Documents

Publication Publication Date Title
JP5166240B2 (en) In vitro method for simultaneous detection and identification of various series of antibiotics and analysis kit by this method
EP2853894B1 (en) Diagnostic kits and immunoassay methods for diagnosis and differentiation of African Swine Fever Virus (ASFV) and Classical Swine Fever Virus (CSFV)
US7691384B2 (en) Method to detect IgE
US9933423B2 (en) Method and device for combined detection of viral and bacterial infections
US4962023A (en) Single incubation immuno sorbent assay method using particle labels to detect test antigen specific antibodies in presence of other antibodies
JP4236629B2 (en) Sandwich analysis test for measuring NT-proBNP
JPH07270422A (en) Method for decreasing coloring in absorbing material layer of testing device and absorbing material layer processed in accordance with method thereof
EP2335072A2 (en) Method and device for combined detection of viral and bacterial infections
JP2011232361A (en) Method of detecting early renal disease in animals
US20090087926A1 (en) Immunochromatographic test device
CA2319310A1 (en) Equine fc epsilon receptor alpha chain nucleic acid molecules, corresponding proteins and uses thereof
EP1960784A1 (en) Detection of secreted aspartyl proteases from candida species
US20210364515A1 (en) Optimizing diagnostics for galactofuranose containing antigens
KR20130090892A (en) Co-coupling to control reactivity of reagents in immunoassays
EP3511712B1 (en) Method for measuring thyroglobulin
EP4161961A2 (en) Detection of antibodies to sars-cov-2
US20100304999A1 (en) System and method for antigen structure-independent detection of antigens captured on antibody arrays
US8716031B2 (en) Method for quantification of antigen-specific canine IgE
US20130217015A1 (en) Hmga2 as a biomarker for diagnosis and prognosis of ovarian cancer
AU4996493A (en) Methods for monitoring effectiveness of interferon therapy in individuals with hcv infections
CN117405470A (en) Immunomagnetic bead kit and application method thereof
JP3227689B2 (en) Anti-neutrophil cytoplasmic antibody measurement method
WO2001034788A1 (en) In-vitro assay for assessment of cytotoxicity of a candidate agent
CN112198313A (en) Kit for PEA detection and use method thereof
CA2329487A1 (en) Assay method

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20190128